Tromethamine

Identification

Name
Tromethamine
Accession Number
DB03754  (EXPT03072)
Type
Small Molecule
Groups
Approved
Description

An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)

Structure
Thumb
Synonyms
  • 1,1,1-tris(hydroxymethyl)methanamine
  • 2-Amino-2-(hydroxymethyl)-1,3-propanediol
  • aminotris(hydroxymethyl)methane
  • THAM
  • Tris
  • Tris(hydroxymethyl)aminomethane
  • Trometamol
  • Tromethamine
External IDs
NSC-6365
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThamInjection, solution3.6 g/100mLIntravenousHospira, Inc.2005-11-302017-06-01Us
Tham Solution 36mg/mlSolutionIntravenousHospira Healthcare Ulc1972-12-312018-10-03Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Sooryehan Hyo Fermented Sun BlockTromethamine (2.63 mL/100mL) + Amiloxate (1.6 mL/100mL) + Bemotrizinol (1 mL/100mL) + Diethylamino hydroxybenzoyl hexyl benzoate (1 mL/100mL) + Ensulizole (3.9 mL/100mL) + Octinoxate (7 mL/100mL) + Titanium dioxide (2.52 mL/100mL)CreamTopicalLg Household & Health Care Ltd.2011-09-27Not applicableUs
Categories
UNII
023C2WHX2V
CAS number
77-86-1
Weight
Average: 121.135
Monoisotopic: 121.073893223
Chemical Formula
C4H11NO3
InChI Key
LENZDBCJOHFCAS-UHFFFAOYSA-N
InChI
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
IUPAC Name
2-amino-2-(hydroxymethyl)propane-1,3-diol
SMILES
NC(CO)(CO)CO

Pharmacology

Indication

For the prevention and correction of metabolic acidosis.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UDNA protection during starvation proteinNot AvailableAgrobacterium tumefaciens (strain C58 / ATCC 33970)
UPutative glucose-6-phosphate 1-epimeraseNot AvailableHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UEndonuclease 8-like 1Not AvailableHumans
UVascular endothelial growth factor ANot AvailableHumans
UDecorinNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Tromethamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

References

Synthesis Reference

Jean Bourguignon, Marcel-Xavier Sion, Michel Moreau, "Preparation of tris(hydroxymethyl)aminomethane." U.S. Patent US4233245, issued August, 1959.

US4233245
General References
Not Available
External Links
Human Metabolome Database
HMDB0240288
KEGG Drug
D00396
KEGG Compound
C07182
PubChem Compound
6503
PubChem Substance
46506027
ChemSpider
6257
RxNav
10865
ChEBI
9754
ChEMBL
CHEMBL1200391
ZINC
ZINC000000896695
PDBe Ligand
TRS
Wikipedia
Tris
ATC Codes
B05XX02 — TrometamolB05BB03 — Trometamol
AHFS Codes
  • 40:08.00 — Alkalinizing Agents
FDA label
Download (88.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
1CompletedPreventionCystic Fibrosis (CF) / Healthy Volunteers1
1CompletedPreventionInfections, Pneumococcal / Infections, Streptococcus Pneumoniae / Pneumonia1
1CompletedPreventionInfections, Pneumococcal / Infections, Streptococcus Pneumoniae / Pneumonia, Pneumococcal2
1CompletedPreventionTuberculosis Infection2
1CompletedTreatmentAdvanced or Metastatic Solid Tumors1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentInflammatory Reaction1
1RecruitingTreatmentAdvanced Adult Primary Liver Cancer / Advanced Gastric Cancer / Advanced or Metastatic CRC / Advanced or Metastatic Gastric Cancer / Advanced or Metastatic Liver Cancer / Advanced or Metastatic Non Squamous NSCLC1
1RecruitingTreatmentPain1
1SuspendedTreatmentCancer, Advanced1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1, 2CompletedPreventionTuberculosis Infection1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Childhood Acute Lymphoblastic Leukemia1
2Not Yet RecruitingTreatmentPain1
2RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Acute Lymphocytic Leukemia (ALL) / Acute, recurrent Myeloid Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Disorders, Lymphoproliferative / Hematopoietic and Lymphoid Cell Neoplasm / High Risk Acute Myeloid Leukemia / High Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent High Risk Myelodysplastic Syndrome / Recurrent Hodgkin Lymphoma / Recurrent Myelodysplastic Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma1
2RecruitingTreatmentGanglioneuroblastoma / High-Risk Neuroblastoma1
2SuspendedTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Lymphoblastic Leukaemia Recurrent / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Undifferentiated Leukemia (AUL) / Acute, recurrent Myeloid Leukemia / Allogeneic Hematopoietic Stem Cell Transplant Recipient / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Donor / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Acute Lymphoblastic Leukemia / Refractory Acute Myelogenous Leukemia (AML)1
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2, 3RecruitingTreatmentMalignancies1
2, 3RecruitingTreatmentPain, Acute1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentUrinary Tract Infection1
3RecruitingTreatmentGanglioneuroblastoma / INRG Stage L2 / INRG Stage M / INRG Stage MS / Neuroblastomas1
4CompletedPreventionAllograft Rejection / Asymptomatic Bacteriuria / Hospitalizations / Microbiologic Resistance / Urinary Tract Infection1
4CompletedTreatmentUrinary Tract Infection1
4RecruitingTreatmentPsychiatric Disorder NOS1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical
Injection, solutionIntravenous3.6 g/100mL
SolutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility695.0 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.7ChemAxon
logS0.76ALOGPS
pKa (Strongest Acidic)14.16ChemAxon
pKa (Strongest Basic)8.95ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area86.71 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity28.36 m3·mol-1ChemAxon
Polarizability12.02 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.52
Blood Brain Barrier-0.6989
Caco-2 permeable-0.6613
P-glycoprotein substrateNon-substrate0.6664
P-glycoprotein inhibitor INon-inhibitor0.9749
P-glycoprotein inhibitor IINon-inhibitor0.9671
Renal organic cation transporterNon-inhibitor0.9239
CYP450 2C9 substrateNon-substrate0.8432
CYP450 2D6 substrateNon-substrate0.8337
CYP450 3A4 substrateNon-substrate0.8096
CYP450 1A2 substrateNon-inhibitor0.8179
CYP450 2C9 inhibitorNon-inhibitor0.9095
CYP450 2D6 inhibitorNon-inhibitor0.9027
CYP450 2C19 inhibitorNon-inhibitor0.895
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9686
Ames testNon AMES toxic0.9257
CarcinogenicityNon-carcinogens0.7844
BiodegradationReady biodegradable0.582
Rat acute toxicity1.5129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9739
hERG inhibition (predictor II)Non-inhibitor0.9664
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-53da6b0f35ab1e8e8a57
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0pi0-7900000000-244b89c0e2e656701b1d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-a468801012da982d3bac
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-eb66f99d48d2027e0fb2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-2983a91b4350760fab44

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
1,2-aminoalcohols
Alternative Parents
Primary alcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
1,2-aminoalcohol / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary alcohol / Organooxygen compound / Primary aliphatic amine / Alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
primary amino compound, triol (CHEBI:9754) / a small molecule (TRIS)

Targets

Kind
Protein
Organism
Agrobacterium tumefaciens (strain C58 / ATCC 33970)
Pharmacological action
Unknown
General Function
Oxidoreductase activity, oxidizing metal ions
Specific Function
Protects DNA from oxidative damage by sequestering intracellular Fe(2+) ion and storing it in the form of Fe(3+) oxyhydroxide mineral, which can be released after reduction. It efficiently inhibits...
Gene Name
dps
Uniprot ID
Q8UCK6
Uniprot Name
DNA protection during starvation protein
Molecular Weight
17822.915 Da
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Carbohydrate binding
Gene Name
Not Available
Uniprot ID
P44160
Uniprot Name
Putative glucose-6-phosphate 1-epimerase
Molecular Weight
Not Available
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
NEIL1
Uniprot ID
Q96FI4
Uniprot Name
Endonuclease 8-like 1
Molecular Weight
43683.625 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
May affect the rate of fibrils formation.
Gene Name
DCN
Uniprot ID
P07585
Uniprot Name
Decorin
Molecular Weight
39746.43 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on May 24, 2020 19:37

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates